Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

67.96 +1.29 (+1.93%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
36 37 Next >
AstraZeneca's Enhertu Cuts Risk Of Death By 36% VsTrastuzumab In Metastatic Breast Cancer
Via Benzinga
US Supports Delay On COVID Patent Waiver Extension Decision
Developing countries have been pushing for a patent waiver extension for COVID-19, which many developed countries argue could discourage pharma companies from responding rapidly to future global health... 
Via Benzinga
Is Amgen Stock a Buy for Income Investors?
Amgen's dividend yield is materially higher than the S&P 500 index's yield. 
Via The Motley Fool
2 Stocks That Could Surprise Investors in 2023
Investing in safe healthcare stocks may be an underrated strategy to deploy. 
Via The Motley Fool
Why Shares of Compugen Rose 16.5% on Wednesday
Market factors and a company announcement helped the stock climb. 
Via The Motley Fool
AstraZeneca PLC (AZN) Q3 2022 Earnings Call Transcript
AZN earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Why AstraZeneca Stock Shot Higher Today
The company trounced analyst profitability estimates for its latest quarter and raised its guidance. 
Via The Motley Fool
Why Are Apellis Pharmaceuticals Shares Falling Today?
Via Benzinga
Analyst Says Coinbase 'A Waste Of Time', Taylor Swift's Concert Fiasco Under DOJ Probe, Shopify Clocks Record Black Friday Sales: Top Stories Monday, Nov. 28
CNBC 
Via Benzinga
AstraZeneca Bets On UK Listed Firm For Lung Diseases
Via Benzinga
European Official Says COVID-19 Booster Uptake Disappointing In The Region
Marco Cavaleri, the European Medicines Agency's (EMA) head of health threats and vaccines strategy, said the recent uptake of COVID-19 vaccine booster doses in the region has been "rather... 
Via Benzinga
Mirati Therapeutics Surges As Big Pharma Reportedly Preps For A Buyout Battle
There are reportedly numerous companies in the mix and they're all awaiting data next month. 
Via Investor's Business Daily
2 Breakout Growth Stocks to Buy for the Long Haul
These two Russell 1000 members know how to grow revenue. 
Via The Motley Fool
2 Stocks to Buy Whether or Not a Recession Is Coming
Both have outperformed the stock market this year. 
Via The Motley Fool
Why Shares of Compugen Jumped 17.86% on Thursday
The company is receiving a $7.5 milestone payment from AstraZeneca for the use of one of its therapies. 
Via The Motley Fool
How Long Can This Top Stock Continue Defying the Bear Market?
It could only be the beginning for this pharma giant. 
Via The Motley Fool
Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says
Via Benzinga
Third COVID-19 Booster or Fifth Dose Not Required Despite Surge In Cases, Australian Health Authorities Say
Australian health authorities have recommended against a fifth COVID-19 vaccine shot despite average daily cases having been 47% higher last week than the week before, said Health Minister Mark Butler... 
Via Benzinga
Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close... 
Via Benzinga
European Medicines Agency's Advisory Committee Backs Approval Of AstraZeneca's Three Cancer Drugs
Via Benzinga
FDA Approves AstraZeneca's Imfinzi/Imjudo Chemo Combo For Late Stage Lung Cancer
Via Benzinga
Repeat COVID-19 Infection Increases Risk Of Acute Outcomes, Long COVID Symptoms, Study Shows
Via Benzinga
AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter Growth
Excluding exchange rates, AstraZeneca's sales surged 19% and came in above forecasts. 
Via Investor's Business Daily
Troubled FTX Faces SEC Probe And 'Urgently Needs' $8B To Avoid Bankruptcy, NIO Posts Wider Q3 Loss, AstraZeneca Ditches US Application Submission For COVID-19 Shot: Top Stories Thursday, Nov. 11
Bloomberg 
Via Benzinga
Apple Hires Facebook Veteran as Information Chief; More Departures Likely
Via Benzinga
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend Stocks
These stocks both pay more than 2% per year in dividends. 
Via The Motley Fool
AstraZeneca Ditches US Application Submission For COVID-19 Shot, Q3 Edges Analyst Expectations On Oncology Strength
Via Benzinga
'Waiting Game Continues' In Emergent BioSolutions, Analysts Cut Price Target
Via Benzinga
FDA Adcomm Backs AstraZeneca's 2-In-1 Asthma Inhaler, Only For Adults Being Less Sure For Adolescents, Kids
Via Benzinga
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022
On CNBC's "Options Action," Michael Khouw of Optimize Advisors said that AstraZeneca plc. (NASDAQ: AZN) traded 3.9 times its average daily put volume on Tuesday. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.